10 results about "Aspirin" patented technology

The application discloses a magnesium complex taking aspirin or an oxygen-deficiency promoting derivative thereof as a ligand, a preparation method and application thereof in preparation of a medicine for treating coronary heart disease. The structural formula of the magnesium complex is shown in the following formula I-IV: the magnesium carbonate is reacted with nitric acid to obtain magnesium nitrate; the aspirin is reacted with sodium bicarbonate to obtain a neutral sodium salt of aspirin; the neutral sodium salt of aspirin is reacted with the magnesium nitrate according to a molar ratio of 1:1 or 2:1 to obtain the magnesium complex shown in the formula I or II. The aspirin is reacted with p-nitrobenzyl alcohol to obtain an oxygen-deficiency promoting derivative of aspirin; the oxygen-deficiency promoting derivative of aspirin is reacted with the magnesium nitrate according to a molar ratio of 1:1 or 2:1 to prepare the magnesium complex shown in the formula III or IV. The application has a remarkable repairing effect on heart damage caused by myocardial ischemia and the like.

This invention discloses the application of a drug in the prevention or treatment of hydrocephalus, belonging to the field of pharmaceutical formulation technology. The drug comprises a pharmaceutically acceptable formulation of one or more of the following active ingredients: compound A, compound B, or compound C, and their pharmaceutically acceptable salts, solvates, or crystal forms; compound A is carbaspirin calcium, compound B is aspirin, and compound C is salicylic acid. This invention utilizes the above-mentioned drug in the prevention or treatment of hydrocephalus. Carbaspirin calcium and its metabolites can significantly reduce ventricular enlargement in a hydrocephalus model rat, and carbaspirin calcium and its metabolites show promise in the preparation of drugs for treating hydrocephalus, providing an effective candidate drug to alleviate the suffering of hydrocephalus patients, reduce treatment risks and costs; it broadens the scope of action of carbaspirin calcium and optimizes the stability formulation of carbaspirin calcium.

Pharmaceutical compositions comprising antioxidants as useful therapeutic agents for treatment of amyotrophic lateral sclerosis (ALS), and methods thereof, are disclosed. In particular, the present disclosure provides enteric capsules and intravenous (i.v.) drip of aspirin-mimetic antioxidant drugs in intervention of ALS.

A liquid composition contains a salicylate compound (e.g. aspirin), glycerin triacetate, saccharin. The salicylate compound is soluble in the composition, which is particularly suitable for oral, parenteral or pulmonary administration.

This invention discloses an isolated anti-FXI and / or anti-FXIa antibody or its antigen-binding fragment, which specifically binds to human FXI or FXIa, and provides a drug targeting FXI that effectively prevents or treats thrombosis with minimal side effects to meet medical needs. Because currently approved anticoagulants interfere with hemostasis, leading to an increased risk of bleeding, there is a significant unmet medical need for safer anticoagulants. Although thrombosis can be treated or prevented with anticoagulants (e.g., heparin, warfarin, aspirin, or factor Xa inhibitors), these treatments have significant adverse effects. Genetic and pharmacological evidence in humans and animals suggests that lowering coagulation factor XI (FXI) can successfully prevent and manage thrombosis with minimal bleeding.

This invention relates to the field of aspirin medicinal chemistry, and particularly to an aspirin-dithiocarbamate hybrid, its preparation method, and its applications. The preparation method uses aspirin (ASP) as the parent compound and involves a three-step reaction: acylation, dithiocarbamate formation, and N-acylation. During this reaction, several novel aspirin-dithiocarbamate hybrids (3a–l) can be efficiently synthesized through a single silica gel column chromatography separation and purification step, making the preparation process simple. The prepared aspirin-dithiocarbamate hybrids significantly enhance the toxicity of human lung cancer cells A549, approximately eight times that of the parent compound ASP, and are comparable to the anticancer drug irinotecan. The prepared aspirin-dithiocarbamate hybrid 3f exhibits inhibitory effects on various cancer cells and can inhibit the growth of human lung cancer A549 cells by inducing cell cycle arrest in the G0 / G1 phase.

The application discloses a preparation method of a dual-function antibacterial and anti-inflammatory absorbable coating material, which comprises the following steps: (1) blending rifampicin, artemisinin and an absorbable polymer A with a mixed solvent to obtain coating solution A; blending minocycline hydrochloride, aspirin and an absorbable polymer B with the mixed solvent to obtain coating solution B; the mixed solvent is selected from hexafluoroisopropanol and ethyl acetate; (2) uniformly spraying the coating solution A and the coating solution B on the surface of a degradable substrate by ultrasonic spraying, and performing drying treatment to obtain the dual-function antibacterial and anti-inflammatory absorbable coating material. According to the preparation method, the proportion of antibiotic active ingredients, anti-inflammatory drug active ingredients and absorbable polymers is regulated, the antibacterial and anti-inflammatory drug coating is uniformly and stably fixed on the surface of the degradable substrate by ultrasonic spraying, and the dual-function absorbable antibacterial and anti-inflammatory coating material with controllable release is prepared by optimizing process parameters.

The present application relates to the technical field of genetic engineering and enzyme engineering, in particular to a kind of lipase mutant and its application in the synthesis of aspirin.The lipase mutant provided by the present application is obtained by joint mutation of the 125th and 198th positions on the amino acid sequence shown in wild-type lipase.The lipase mutant constructed by the present application exhibits ultra-high activity in the synthesis of aspirin, and can be applied to the preparation of aspirin.The present application also provides a green high-yield preparation process of aspirin, which uses the lipase mutant to synthesize aspirin in a non-aqueous phase or a solvent-free system, and the substrate conversion rate can reach 99.9%, without by-product, and the product has high purity, which can meet the growing demand of market for aspirin, and has good industrial popularization value.

1. Name of the product in this design: Packaging Box (Aspirin Enteric-coated Tablets). 2. Purpose of this design: For use in pharmaceutical packaging boxes. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key features: the front view. 5. The design for which protection is sought includes color.